Media Room
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
June 23, 2026
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
June 23, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
June 22, 2026
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
October 2025
Annual Report on Form 20-F
Annual Report on Form 20-F 2025
October 2025
Annual Report on Form 20-F
Viewer XBRL ESEF (fr)
July 2025
Half-year Financial Reports
Half Year 2025 Financial Report
July 2025
Half-year Financial Reports
Half year 2025 financial report XBRL package